LY2795050 is primarily used in research settings to study the role of kappa opioid receptors (KOR) in the brain. It acts as a selective antagonist, blocking these receptors to help scientists understand their function in pain modulation, mood regulation, and addiction. This compound is particularly valuable in preclinical studies aimed at exploring potential treatments for conditions like depression, anxiety, and substance abuse disorders. By inhibiting KOR activity, LY2795050 helps researchers investigate the receptor's involvement in stress responses and reward pathways, providing insights that could lead to the development of novel therapeutic agents.